@Article{info:doi/10.2196/56048,
author="Hoadley, Ariel
and Fleisher, Linda
and Kenny, Cassidy
and Kelly, Patrick JA
and Ma, Xinrui
and Wu, Jingwei
and Guerra, Carmen
and Leader, Amy E
and Alhajji, Mohammed
and D'Avanzo, Paul
and Landau, Zoe
and Bass, Sarah Bauerle",
title="Exploring Racial Disparities in Awareness and Perceptions of Oncology Clinical Trials: Cross-Sectional Analysis of Baseline Data From the mychoice Study",
journal="JMIR Cancer",
year="2024",
month="Sep",
day="30",
volume="10",
pages="e56048",
keywords="oncology clinical trial; cancer; decision-making; racial disparity; medical mistrust",
abstract="Background: Black/African American adults are underrepresented in oncology clinical trials in the United States, despite efforts at narrowing this disparity. Objective: This study aims to explore differences in how Black/African American oncology patients perceive clinical trials to improve support for the clinical trial participation decision-making process. Methods: As part of a larger randomized controlled trial, a total of 244 adult oncology patients receiving active treatment or follow-up care completed a cross-sectional baseline survey on sociodemographic characteristics, clinical trial knowledge, health literacy, perceptions of cancer clinical trials, patient activation, patient advocacy, health care self-efficacy, decisional conflict, and clinical trial intentions. Self-reported race was dichotomized into Black/African American and non--Black/African American. As appropriate, 2-tailed t tests and chi-square tests of independence were used to examine differences between groups. Results: Black/African American participants had lower clinical trial knowledge (P=.006), lower health literacy (P<.001), and more medical mistrust (all P values <.05) than non--Black/African American participants. While intentions to participate in a clinical trial, if offered, did not vary between Black/African American and non--Black/African American participants, Black/African American participants indicated lower awareness of clinical trials, fewer benefits of clinical trials, and more uncertainty around clinical trial decision-making (all P values <.05). There were no differences for other variables. Conclusions: Despite no significant differences in intent to participate in a clinical trial if offered and high overall trust in individual health care providers among both groups, beliefs persist about barriers to and benefits of clinical trial participation among Black/African American patients. Findings highlight specific ways that education and resources about clinical trials could be tailored to better suit the informational and decision-making needs and preferences of Black/African American oncology patients. ",
issn="2369-1999",
doi="10.2196/56048",
url="https://cancer.jmir.org/2024/1/e56048",
url="https://doi.org/10.2196/56048"
}